| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
Purine nucleoside metabolism pathways; DNA synthesis. As a purine nucleoside analog, 5-Iodo-cytidine is incorporated into DNA, disrupting nucleic acid synthesis. The compound targets rapidly dividing cells, particularly lymphoid malignancies. The iodine atom at the 5-position may confer photoreactivity and facilitate detection.
|
|---|---|
| ln Vitro |
5-Iodo-cytidine demonstrates activity as a purine nucleoside analog in cellular assays. It exhibits notable antitumor activity, particularly against indolent lymphoid malignancies. The compound inhibits DNA synthesis and induces apoptosis in cancer cells. Detailed IC50 values have not been disclosed.
|
| ln Vivo |
In vivo activity of 5-Iodo-cytidine has not been extensively characterized. As a purine nucleoside analog, it would be expected to have antitumor activity in animal models of lymphoid malignancies. Its halogenated structure may enable imaging or therapeutic applications. In vivo studies would be needed to evaluate its therapeutic potential.
|
| Enzyme Assay |
In vitro assays for purine nucleoside analogs typically involve measuring inhibition of DNA synthesis using radiolabeled thymidine incorporation. The compound is incubated with cancer cells at varying concentrations, and incorporation of labeled nucleosides is measured. Cell viability is assessed by MTT or CellTiter-Glo assays. Apoptosis is evaluated by caspase activation or Annexin V staining.
|
| Cell Assay |
Cells (e.g., lymphoid malignancy cell lines or other cancer cell lines) are cultured and treated with 5-Iodo-cytidine at concentrations typically ranging from 0.1–100 μM for 24–72 hours. DNA synthesis inhibition is measured by BrdU incorporation. Cell viability is assessed by standard assays. Apoptosis is evaluated by flow cytometry or Western blot for cleaved caspases.
|
| Animal Protocol |
In vivo animal studies for 5-Iodo-cytidine have not been reported. The compound is primarily used as a research tool and building block for nucleoside analog studies. Future studies in xenograft models would be needed to evaluate in vivo efficacy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 5-Iodo-cytidine have not been published. The compound has a molecular weight of 369.11 and formula C9H12IN3O5. The iodine atom may affect metabolic stability and tissue distribution. In vivo PK parameters have not been characterized.
|
| Toxicity/Toxicokinetics |
Toxicology data for 5-Iodo-cytidine have not been published. The compound is for research use only and not approved for human therapeutic applications. No systematic toxicological evaluation has been performed. Standard safety precautions for handling halogenated nucleoside analogs should be observed.
|
| References | |
| Additional Infomation |
5-Iodo-cytidine (CAS: 1147-23-5, molecular formula C9H12IN3O5, molecular weight 369.11) is a halogenated purine nucleoside analog. It exhibits notable antitumor activity against indolent lymphoid malignancies. It is used as a building block and probe in biochemical and medicinal chemistry research. It is not in clinical trials and has no regulatory approval.
|
| Molecular Formula |
C9H12IN3O5
|
|---|---|
| Molecular Weight |
369.11
|
| Exact Mass |
368.982
|
| CAS # |
1147-23-5
|
| PubChem CID |
159359
|
| Appearance |
White to off-white solid powder
|
| Density |
2.52 g/cm3
|
| Boiling Point |
565.5ºCat 760 mmHg
|
| Flash Point |
295.8ºC
|
| Vapour Pressure |
3.85E-15mmHg at 25°C
|
| Index of Refraction |
1.85
|
| LogP |
-1.7
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
426
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=C(C(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N)I
|
| InChi Key |
LQQGJDJXUSAEMZ-UAKXSSHOSA-N
|
| InChi Code |
InChI=1S/C9H12IN3O5/c10-3-1-13(9(17)12-7(3)11)8-6(16)5(15)4(2-14)18-8/h1,4-6,8,14-16H,2H2,(H2,11,12,17)/t4-,5-,6-,8-/m1/s1
|
| Chemical Name |
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7092 mL | 13.5461 mL | 27.0922 mL | |
| 5 mM | 0.5418 mL | 2.7092 mL | 5.4184 mL | |
| 10 mM | 0.2709 mL | 1.3546 mL | 2.7092 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
